The $100 billion opportunity: How anti-obesity drugs are reshaping healthcare and consumer behavior
Goldman Sachs Exchanges
00:00
Pricing and Performance of Anti-Obesity Stocks
An analysis of the pricing and performance of stocks within the anti-obesity sector, including the underperformance of food stocks and the debate about concentration of pricing within the sector.
Transcript
Play full episode
